论文部分内容阅读
目的应用Meta分析方法进一步了解丹参川芎嗪注射液治疗急性脑梗死的临床疗效和安全性.方法检索中国期刊网全文数据库2000年至2011年关于丹参川芎嗪注射液治疗急性脑梗死的文章,主题词包括丹参川芎嗪和急性脑梗死.共有9篇文章最终入选,并采用RevMan 5.1软件进行Meta分析.结果共纳入9篇随机对照研究(共977例患者).与对照组比较,丹参川芎嗪注射液可明显提高急性脑梗死患者的治愈率[OR合并值=2.35,95%CI=(1.68,3.29), Z=4.98,P<0.00001];总有效率比较,两组间差异具有统计学意义[OR合并值=3.58,95%CI=(2.55,5.01),Z=7.39,P<0.00001].结论现有的证据表明,丹参川芎嗪注射液与丹参注射液比较,可以提高脑梗塞患者的治愈率和总有效率.由于目前临床研究质量较低,尚需严格设计的、多中心的随机对照试验加以证实.“,”Objective To further investigate the clinical effectiveness and reliability of Salvia Miltiorrhiza Ligustrazine Injection in the treatment of acute cerebral infarction by using Meta-analysis. Methods Using the key terms of “alvia Miltiorrhiza Ligustrazine, acute cerebral infarction”,we searched the Chinese Journals Ful-text Database for the articles about the treatment of acute cerebral infarction by Salvia Miltiorrhiza Ligustrazine Injection published from January 2000 to 2011.Then 9 articles were retrieved and RevMan 5.1 software was used for data analysis. Results Nine RCTs involving 977 patients with acute cerebral infarction were included. Salvia Miltiorrhiza Ligustrazine Injection was more effective in increasing cure rate and total effective rate compared with the control group[OR合并值=2.35,95%CI=(1.68,3.29),Z=4.98,P<0.00001; OR合并值=3.58,95%CI=(2.55,5.01), Z=7.39,P<0.00001]. Conclusions The limited evidences showed that Salvia Miltiorrhiza Ligustrazine Injection may increase the cure rate and total effective rate of acute cerebral infarction. Large-scale and wel-designed clinical trials are needed to give more peruasive evidences to prove the efficacy of Salvia Miltiorrhiza Ligustrazine Injection due to some low-quality trials.